Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class

MedChemComm
Paula Nogueira da SilvaMaria Leticia de Castro Barbosa

Abstract

Diabetes mellitus is a chronic, complex and multifactorial disease associated characteristically with hyperglycemia. One of the most recently approved antidiabetic drug classes for clinical use are sodium-glucose cotransporter type 2 (SGLT-2) inhibitors. SGLT-2 is a protein expressed in the kidneys, responsible for glucose reabsorption from the glomerular filtrate to the plasma. It is known, nowadays, that diabetic patients show an increased glucose renal reabsorption capacity, caused by the overexpression of the SGLT-2 transporter, thus contributing to hyperglycemia. From establishing this correlation, the SGLT-2 transporter started to be considered as a therapeutic target of interest, culminating in the approval of the first antidiabetic SGLT-2 inhibitor, dapagliflozin (Forxiga® or Farxiga®, Bristol-Myers Squibb & AstraZeneca), in 2012 in Europe. On the other hand, canagliflozin (Invokana®, Janssen Pharmaceutical) was the first drug in this class to be approved by the FDA, the U.S. Food and Drug Administration, in 2013. This review concerns the discovery and development of the first representatives of this class of antidiabetic drugs, and the description of new optimized analogues that are currently in the clinical and precli...Continue Reading

References

Aug 6, 2004·Journal of Medicinal Chemistry·Jay S Skyler
Dec 30, 2004·Diabetes/metabolism Research and Reviews·Joel R L EhrenkranzJesse Roth
Aug 19, 2008·Bioorganic & Medicinal Chemistry Letters·Bruce A EllsworthWilliam N Washburn
May 20, 2011·Bioorganic & Medicinal Chemistry Letters·Suk Youn KangJinhwa Lee
Sep 13, 2011·Bioorganic & Medicinal Chemistry·Suk Ho LeeJinhwa Lee
Jul 16, 2013·Lancet·Michaela Diamant, Linde M Morsink
Sep 4, 2013·Bioorganic & Medicinal Chemistry Letters·Yasuo YamamotoSumihiro Nomura
Oct 22, 2013·Natural Product Reports·Armin Bauer, Mark Brönstrup
Apr 17, 2014·Diabetes Research and Clinical Practice·Farhad M HasanJohn E Gerich
May 24, 2014·Nature Reviews. Drug Discovery·Marc Y Donath
Jun 6, 2014·ACS Medicinal Chemistry Letters·Sumihiro NomuraMinoru Tsuda-Tsukimoto
Feb 19, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Pablo LapuertaArthur Sands
Dec 4, 2016·Journal of Diabetes and Its Complications·Juliette Sandifer Kum-NjiSamuel Dagogo-Jack
Jan 26, 2017·Current Pharmaceutical Design·Konstantinos ImprialosMichael Doumas
Jun 2, 2017·Diabetes Research and Clinical Practice·Matteo MonamiEdoardo Mannucci
Sep 14, 2017·The New England Journal of Medicine·Satish K GargPaul Strumph
Oct 19, 2017·Drug Design, Development and Therapy·Francesca CintiAndrea Giaccari

❮ Previous
Next ❯

Citations

Dec 21, 2018·Endocrine, Metabolic & Immune Disorders Drug Targets·Oğuz AkkuşOnur Kaypaklı
Mar 2, 2021·Frontiers in Cardiovascular Medicine·Qingchun ZengDingli Xu
May 25, 2021·CJC Open·Ammar G ChaudharyMohammad A Aziz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.